Confocal immunofluorescent analysis of IGROV-1 cells, treated with LY294002 #9901 (50 μM, 3hr; left), insulin (100 ng/mL, 30 min; middle), or Leptomycin B followed by insulin (20 nM, 3hr and 100 ng/mL, 30 min, respectively; right), using FoxO1 (C29H4) Rabbit mAb #2880 (green). Actin filaments were labeled with DY-554 phalloidin (red).
Chemical structure of Leptomycin B
Leptomycin B is supplied as a 200 μM solution in ethanol. All dilutions, except the final dilution, must be performed in ethanol. Final dilutions can be performed in culture media. Working concentrations and length of treatment can vary depending on the desired effect, but 5-80 nM for 3 hours generally inhibits most nuclear export. Soluble and stable in ethanol. Leptomycin B is not stable in DMSO; do not dilute in DMSO.
In order to minimize evaporation, it is recommended that the LMB vial be kept on ice when in use.
Stability Warning: LMB in any quantity is unstable when dried down into a film. Thus, under no circumstances should the solvent be removed from solutions of LMB because rapid decomposition and loss of recoverable material will result.
Store solution at -20ºC. Protect from light. If stored and handled appropriately, it will be stable for 12 months.
|Molecular Weight||540.73 g/mol|
|Solubility||Soluble in EtOH.|
Leptomycin B (LMB), originally discovered and utilized as a potent anti-fungal antibiotic from Streptomyces sp., has more recently been identified to inhibit nuclear export of proteins and RNA containing a Nuclear Export Sequence (NES) (1). The mechanism behind LMB's potent inhibition is achieved by specifically binding to chromosomal region maintenance (CRM)/exportin 1 protein; CRM1 binds to ribonuclear proteins containing the NES (1,2). LMB has also been reported to inhibit the degradation and subsequently lead to accumulation of p53 within the nucleus (3) and has demonstrated specific anti-tumor properties, although toxic, at high doses (1-3).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.